2023
DOI: 10.1177/10781552231212640
|View full text |Cite
|
Sign up to set email alerts
|

Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions

Molly Lofy,
Lindsey Jung,
Elizabeth Dow-Hillgartner

Abstract: Introduction Cetuximab, an IgG1 monoclonal antibody, is utilized in the treatment of metastatic colorectal cancer and squamous cell head and neck cancers. Due to the risk of hypersensitivity reactions, standard premedication with a histamine-1 (H-1) antagonist is recommended prior to administration, however, there is less guidance for premedication strategies to assist with rechallenge after infusion reactions. Here, we describe two cases of successful cetuximab treatment after Grade 2 reactions, in addition t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
references
References 8 publications
0
0
0
Order By: Relevance